Can an endometriotic ovarian cyst (endometrioma) shrink in size and later disappear completely?

Can Endometriotic Ovarian Cysts Shrink and Disappear?

Yes, endometriomas can shrink in size and occasionally disappear completely, particularly during pregnancy or with hormonal suppression therapy, though spontaneous resolution without intervention is less common in non-pregnant women.

Natural History Without Intervention

In Non-Pregnant Women

• Most endometriomas remain stable or slowly progress when managed expectantly 1
• In a cohort of 83 women with endometriomas followed conservatively, 47% experienced overall size reduction, 31% remained unchanged, and only 22% increased in size 1
• The median annual regression rate was -1.7 mm/year, with cysts significantly smaller at follow-up compared to initial diagnosis (median 22.3 mm vs 18.5 mm) 1
• Complete spontaneous disappearance is uncommon in non-pregnant women without hormonal therapy 1

During Pregnancy

• Pregnancy has a profound beneficial effect on endometriomas, with approximately two-thirds decreasing in size 2
• In one study, 40% of endometriomas became completely undetectable after delivery, 27% remained unchanged, and only 5% increased in size 2, 3
• Among 24 pregnant women carrying 40 endometriomas, 46% had no detectable cyst after delivery 3
• The mean diameter reduction during pregnancy was not statistically significant overall, but the number of cysts per patient significantly decreased (p=0.003) 3

Important caveat: While most endometriomas shrink during pregnancy, 2.8% may rupture, particularly those ≥6 cm, those with adhesions, or those experiencing size increase 2

Medical Management Effects

Hormonal Suppression Therapy

• Hormonal treatment can substantially reduce endometrioma size, with a mean volume reduction of 55% at 6 months across all hormonal therapies 4
• Dienogest is highly effective, reducing cyst diameter by 1.32 cm (95% CI: 0.91-1.73) and showing significant volume reduction (mean difference of log-transformed volume 1.35) 5
• Oral contraceptive pills reduce diameter by 1.06 cm (95% CI: 0.59-1.53) 5
• GnRH agonists reduce diameter by 1.17 cm (95% CI: 0.42-1.92) 5
• Norethindrone acetate with aromatase inhibitor shows volume reduction (mean difference 1.47) 5

Time Course of Response

• Volume reduction becomes statistically significant at 6 months of hormonal therapy 4
• The greatest reductions occur with dienogest and norethindrone acetate plus letrozole, followed by relugolix and leuprolide acetate 4
• Combined hormonal contraceptives and other progestins show less consistent volume reduction 4

Management Algorithm Based on Guidelines

For Endometriomas <10 cm in Premenopausal Women

• Optional initial follow-up at 8-12 weeks based on confidence in diagnosis 6
• If not surgically removed, annual ultrasound surveillance should be considered 6
• These patients are typically under gynecologist care 6

For Endometriomas in Postmenopausal Women

• Annual ultrasound follow-up may be considered when not surgically excised 6
• Higher vigilance required due to increased risk of malignant transformation (clear cell and endometrioid carcinomas) 6
• If changing morphology or developing vascular component appears, refer to ultrasound specialist or perform MRI in premenopausal women; direct MRI referral in postmenopausal women 6

Key Clinical Pitfalls to Avoid

• Do not assume all endometriomas will spontaneously resolve: Only a minority completely disappear without intervention 1
• Pregnancy-related changes can mimic malignancy: Endometriomas can undergo decidualization, enlarging and developing vascularized papillary projections that mimic malignancy 7
• Loss of typical appearance during pregnancy: Hormonal progesterone stimulation can alter the classic ultrasound appearance, making diagnosis difficult 7
• Rupture risk during pregnancy: While uncommon (2.8%), rupture is more likely with cysts ≥6 cm, those with adhesions, or those increasing in size 2
• Postmenopausal endometriomas require heightened surveillance due to malignant transformation risk 6

Predictors of Size Change

• No reliable clinical characteristics have been identified that predict endometrioma progression or regression in non-pregnant women 1
• Smaller endometriomas (<5 cm) are more likely to disappear during pregnancy 3
• Serum AQP9 levels inversely correlate with endometrioma size (p=0.008), though clinical utility remains investigational 8